Physician profile
Chase V Hunter
NPI 1457542060
$1,555.13
in general payments reported to CMS, 2019-2025
12 companies · $624 in 2025
The $624 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2021: $56.61 · 2022: $300 · 2023: $334 · 2024: $123 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026 · Entertainment: $54.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.51 |
| Entertainment | $54.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $765.32 | 2021-2025 | Precision 1, Total30, Precision7 |
| Bausch & Lomb Americas INC. | $298.67 | 2022-2025 | Infuse, Biotrue One Day, Prolensa |
| Sun Pharmaceutical Industries INC. | $126.39 | 2023-2025 | Cequa |
| Shire North American Group INC | $118.16 | 2019 | |
| Optos, INC. | $54.69 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Oyster Point Pharma, INC. | $47.40 | 2022 | |
| Coopervision INC. | $47.03 | 2021-2025 | Misight Contact Lens |
| Lombart Brothers, INC. | $34.48 | 2025 | Opd-III |
| Dompe US, INC. | $20.23 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $17.67 | 2024 | Xdemvy |
| Allergan, INC. | $13.91 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.